Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

FDA approves Convenia RTU ahead of Q3 results for Zoetis stock

Analyst downgrade Dividend Drug approval AI-generated analysis

πŸ“… FDA approved Convenia RTU for dogs on October 20, 2026, expanding Zoetis' companion-animal portfolio with a ready-to-use antibiotic.

πŸ’‰ The new Convenia RTU product provides up to 14 days of antibiotic coverage from a single injection for bacterial skin infections.

πŸš€ Zoetis is expected to launch the new antibiotic product with veterinarians in the first quarter of 2027.

πŸ’° Second-quarter 2026 revenue reached USD 2.47 billion, demonstrating strong top-line growth.

πŸ“ˆ Diluted earnings per share for Q2 2026 were USD 1.65, reflecting solid profitability.

πŸ’Έ Zoetis declared a quarterly dividend of USD 0.53 on October 8, 2026, with a record date of October 30, 2026.

πŸ“‰ Jefferies cut its price target from USD 103 to USD 83 and downgraded the stock from Buy to Hold on October 20, 2026.

⚠️ Analysts cite pricing pressure and competitive risks as key concerns weighing on expectations despite pipeline expansion.

πŸ“Š Zoetis stock was trading at EUR 70.40 on October 29, 2026, with a market capitalization of USD 32.1 billion.

πŸ—“οΈ Third-quarter results are scheduled for release on November 5, 2026, following the Q2 reporting period.

Bullish Signals
  • Zoetis received FDA approval for Convenia RTU, a ready-to-use canine antibiotic that provides up to 14 days of treatment from one injection.
  • The new product expands options for treating bacterial skin infections in dogs, including pyoderma, abscesses, and wounds.
  • Second-quarter 2026 revenue reached USD 2.47 billion, indicating strong commercial performance.
  • Diluted earnings per share were USD 1.65 in Q2 2026, demonstrating healthy profitability.
  • Zoetis declared a quarterly dividend of USD 0.53 on October 8, 2026, returning capital to shareholders.
Risk Factors
  • Jefferies downgraded Zoetis from Buy to Hold and cut its price target from USD 103 to USD 83 due to pricing pressure.
  • Analysts warn that competitive risks in the veterinary pharmaceutical sector are weighing on future expectations.
  • The contrast between pipeline expansion and financial headwinds suggests potential margin compression ahead of Q3 results.
Full Analysis
Zoetis (ZTS) received FDA approval for Convenia RTU, a ready-to-use antibiotic for dogs, on October 20, 2026. This new product adds to the company's companion-animal portfolio by offering up to 14 days of treatment from a single injection for bacterial skin infections like pyoderma and abscesses. The product is expected to reach veterinarians in the first quarter of 2027. Financially, Zoetis reported strong second-quarter 2026 performance with revenue reaching USD 2.47 billion and diluted earnings per share of USD 1.65. The company also declared a quarterly dividend of USD 0.53 on October 8, 2026, with a record date set for October 30, 2026. These figures highlight the robust cash flow supporting shareholder returns despite market headwinds. Despite the product expansion, analyst sentiment has turned cautious due to pricing pressures and competitive risks in the sector. Jefferies downgraded its rating on Zoetis from Buy to Hold and cut its price target from USD 103 to USD 83 on October 20, 2026. The company is preparing to release third-quarter results on November 5, 2026, which will likely reflect the ongoing balance between pipeline growth and margin challenges.